Nasdaq
$72.67▲ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.65BShares out 22.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 10.16After-hours26.10.17 07:504Ownership#●●●
ANI PHARMACEUTICALS INC
Nikhil Lalwani, an insider at ANI Pharmaceuticals, reported a change in his beneficial ownership of company securities on October 15, 2026. This filing serves as a Form 4 statement regarding the executive's stock holdings.…more
$72.67+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:25144Ownership
ANI PHARMACEUTICALS INC
Nikhil Lalwani, an insider at ANI PHARMACEUTICALS INC, has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard insider filing disclosing the executive's plan to dispose of their holdings.…more
$72.67+0.08%vs prev closeView filingShare - 10.14Overnight26.10.14 09:474Ownership
ANI PHARMACEUTICALS INC
Insider Meredith Cook of ANI Pharmaceuticals filed a Form 4 on October 13, 2026, reporting changes in beneficial ownership of securities. This filing reflects updates to the insider's equity holdings.…more
$72.67+0.08%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 19:55#●●●#●●●
ANI Pharmaceuticals Announces Q3 2026 Earnings Release Date
ANI Pharmaceuticals will release its third quarter 2026 financial results on November 5, 2026. The company will host a conference call and webcast with its executive team to discuss the quarterly performance.…more
$72.67+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 6d agoPre-market26.10.19 19:55
●●●●●●●● ●●●●● ●●●●●●
ANI Pharmaceuticals has launched its generic version of the Duloxetine delayed-release capsules, targeting a market with approximately $247 million in annual sales. This move expands the company's generics portfolio and aims to provide a stable supply in a limited-player market.…more
$72.67+0.08%vs prev close - 10.12Pre-market26.10.12 19:55
●●●●●●●● ●●●●● ●●●●●●
ANI Pharmaceuticals announced positive 6-month and 24-month data from its Phase 4 SYNCHRONICITY trial for its chronic non-infectious uveitis treatment. The study met its primary endpoints, demonstrating sustained improvements in visual acuity and inflammation control.…more
$72.67+0.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report